Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121


False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.

Nunes CB, Rocha RM, Buzelin MA, Balabram D, de Souza Foureaux F, Porto SS, Gobbi H.

J Clin Pathol. 2013 Nov;66(11):946-50. doi: 10.1136/jclinpath-2013-201647. Epub 2013 Jul 18.


Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.

Nunes CB, Rocha RM, Reis-Filho JS, Lambros MB, Rocha GF, Sanches FS, Oliveira FN, Gobbi H.

J Clin Pathol. 2008 Aug;61(8):934-8. doi: 10.1136/jcp.2007.053892. Epub 2008 May 12.


HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.

Ricardo SA, Milanezi F, Carvalho ST, Leitão DR, Schmitt FC.

J Clin Pathol. 2007 Sep;60(9):1001-5. Epub 2006 Dec 8.


Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J.

Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20.


Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.


HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.

Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH, Scapulatempo-Neto C.

World J Gastroenterol. 2013 Oct 14;19(38):6438-46. doi: 10.3748/wjg.v19.i38.6438.


Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.

Cho EY, Srivastava A, Park K, Kim J, Lee MH, Do I, Lee J, Kim KM, Sohn TS, Kang WK, Kim S.

Pathology. 2012 Apr;44(3):216-20. doi: 10.1097/PAT.0b013e3283513e8b.


HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL.

Mod Pathol. 2001 Nov;14(11):1079-86.


Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.

Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res. 2012 Jun 13;14(3):R93.


Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.

Gouvêa AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H.

Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):103-8.


A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice.

Manion E, Hornick JL, Lester SC, Brock JE.

Am J Clin Pathol. 2011 Jun;135(6):845-51. doi: 10.1309/AJCPIP5LOO3NGDJG.


HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

Kovács A, Stenman G.

Pathol Res Pract. 2010 Jan 15;206(1):39-42. doi: 10.1016/j.prp.2009.08.003. Epub 2009 Oct 12.


A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR.

Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.


High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer: whole slide imaging for the assessment of HER2 expression.

Nunes C, Rocha R, Buzelin M, Balabram D, Foureaux F, Porto S, Gobbi H.

Pathol Res Pract. 2014 Nov;210(11):713-8. doi: 10.1016/j.prp.2014.06.031. Epub 2014 Jul 16.


Evaluating HER2 amplification and overexpression in breast cancer.

Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG.

J Pathol. 2001 Nov;195(4):422-8.


HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Boers JE, Meeuwissen H, Methorst N.

Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.


HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.

Cappellesso R, Fassan M, Hanspeter E, Bornschein J, d'Amore ES, Cuorvo LV, Mazzoleni G, Barbareschi M, Pizzi M, Guzzardo V, Malfertheiner P, Micev M, Guido M, Giacomelli L, Tsukanov VV, Zagonel V, Nitti D, Rugge M.

Hum Pathol. 2015 May;46(5):665-72. doi: 10.1016/j.humpath.2015.02.007. Epub 2015 Feb 27.


IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.

Ainsworth R, Bartlett JM, Going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B.

J Clin Pathol. 2005 Oct;58(10):1086-90.


Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.

Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V.

Histopathology. 2003 Apr;42(4):337-47.


Supplemental Content

Support Center